Answers are grounded in this paper and cite their sources.
Objective To investigate the diagnostic value of serum bone metabolism markers in diabetic foot osteomyelitis (DFO). Methods This pilot, single-center case-control study included 35 patients with DFO and 33 without DFO. All biomarkers were measured from a single fasting blood sample collected after admission. Between-group comparisons were performed using independent-samples t tests or Mann–Whitney U tests. Receiver operating characteristic (ROC) curves were used to evaluate diagnostic performance, and multivariable linear regression assessed associations between parathyroid hormone (PTH) and clinical and biochemical parameters. A sensitivity analysis was performed using biopsy-confirmed DFO cases and non-DFO controls. Results Median serum PTH was higher in the DFO group than in the non-DFO group (34.94 vs. 24.76 ng/L, P = 0.029). The area under the curve (AUC) for PTH was 0.65 (95% confidence interval (CI), 0.52-0.79), compared with 0.74 for white blood cell count (WBC); adding PTH to WBC did not significantly improve discrimination. No significant between-group differences were observed in corrected calcium, serum phosphorus, or the other bone metabolism markers, including alkaline phosphatase (ALP), 25-hydroxyvitamin D [25(OH)D], calcitonin (CT), C-terminal telopeptide of type I collagen (CTX), procollagen type I N-terminal propeptide (P1NP), and osteocalcin (OC) (all P > 0.05). The analysis of 30 biopsy-confirmed DFO cases and 33 non-DFO cases yielded similar findings (PTH AUC = 0.67; 95% CI, 0.53-0.80). In multivariable linear regression, C-reactive protein (CRP) was positively associated with PTH (β = 0.12, 95% CI, 0.03-0.22; P = 0.014), whereas DFO status was not significantly associated with PTH (β = 5.34, 95% CI, -3.29-13.96; P = 0.221). Conclusion Serum PTH concentrations were elevated in patients with DFO and were positively associated with CRP after adjustment. PTH showed a modest AUC of 0.65. Higher PTH levels in patients with DFO may reflect more severe infection rather than osteomyelitis due to inconsistent severity of infection. This pilot study does not support the use of bone metabolism markers as stand-alone diagnostic tests for DFO.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: